193 related articles for article (PubMed ID: 16794269)
1. Intracoronary infusion of CD133+ and CD133-CD34+ selected autologous bone marrow progenitor cells in patients with chronic ischemic cardiomyopathy: cell isolation, adherence to the infarcted area, and body distribution.
Goussetis E; Manginas A; Koutelou M; Peristeri I; Theodosaki M; Kollaros N; Leontiadis E; Theodorakos A; Paterakis G; Karatasakis G; Cokkinos DV; Graphakos S
Stem Cells; 2006 Oct; 24(10):2279-83. PubMed ID: 16794269
[TBL] [Abstract][Full Text] [Related]
2. Improved mobilization of the CD34(+) and CD133(+) bone marrow-derived circulating progenitor cells by freshly isolated intracoronary bone marrow cell transplantation in patients with ischemic heart disease.
Turan RG; Bozdag-Turan I; Ortak J; Akin I; Kische S; Schneider H; Turan CH; Rehders TC; Rauchhaus M; Kleinfeldt T; Adolph E; Brehm M; Yokus S; Steiner S; Sahin K; Nienaber CA; Ince H
Stem Cells Dev; 2011 Sep; 20(9):1491-501. PubMed ID: 21190450
[TBL] [Abstract][Full Text] [Related]
3. Pilot study to evaluate the safety and feasibility of intracoronary CD133(+) and CD133(-) CD34(+) cell therapy in patients with nonviable anterior myocardial infarction.
Manginas A; Goussetis E; Koutelou M; Karatasakis G; Peristeri I; Theodorakos A; Leontiadis E; Plessas N; Theodosaki M; Graphakos S; Cokkinos DV
Catheter Cardiovasc Interv; 2007 May; 69(6):773-81. PubMed ID: 17394248
[TBL] [Abstract][Full Text] [Related]
4. In vivo visualization of 111In labeled CD133+ peripheral blood stem cells after intracoronary administration in patients with chronic ischemic heart disease.
Caveliers V; De Keulenaer G; Everaert H; Van Riet I; Van Camp G; Verheye S; Roland J; Schoors D; Franken PR; Schots R
Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):61-6. PubMed ID: 17372574
[TBL] [Abstract][Full Text] [Related]
5. Evidence that intracoronary-injected CD133+ peripheral blood progenitor cells home to the myocardium in chronic postinfarction heart failure.
Schots R; De Keulenaer G; Schoors D; Caveliers V; Dujardin M; Verheye S; Van Camp G; Franken PR; Roland J; Van Riet I; Everaert H
Exp Hematol; 2007 Dec; 35(12):1884-90. PubMed ID: 17923244
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing spontaneous mobilization of CD34+ and CD133+ progenitor cells after myocardial infarction.
Turan RG; Brehm M; Koestering M; Tobias Z; Bartsch T; Steiner S; Picard F; Ebner P; Schannwell CM; Strauer BE
Eur J Clin Invest; 2007 Nov; 37(11):842-51. PubMed ID: 17973780
[TBL] [Abstract][Full Text] [Related]
7. Proliferation and differentiation potential of CD133+ and CD34+ populations from the bone marrow and mobilized peripheral blood.
Koutna I; Peterkova M; Simara P; Stejskal S; Tesarova L; Kozubek M
Ann Hematol; 2011 Feb; 90(2):127-37. PubMed ID: 20821012
[TBL] [Abstract][Full Text] [Related]
8. Intramyocardial delivery of human CD133+ cells in a SCID mouse cryoinjury model: Bone marrow vs. cord blood-derived cells.
Ma N; Ladilov Y; Moebius JM; Ong L; Piechaczek C; Dávid A; Kaminski A; Choi YH; Li W; Egger D; Stamm C; Steinhoff G
Cardiovasc Res; 2006 Jul; 71(1):158-69. PubMed ID: 16730684
[TBL] [Abstract][Full Text] [Related]
9. Implantation of CD133+ stem cells in patients undergoing coronary bypass surgery: IMPACT-CABG pilot trial.
Forcillo J; Stevens LM; Mansour S; Prieto I; Salem R; Baron C; Roy DC; Larose E; Masckauchan D; Noiseux N
Can J Cardiol; 2013 Apr; 29(4):441-7. PubMed ID: 23265095
[TBL] [Abstract][Full Text] [Related]
10. Autologous mesenchymal stem cells mobilize cKit+ and CD133+ bone marrow progenitor cells and improve regional function in hibernating myocardium.
Suzuki G; Iyer V; Lee TC; Canty JM
Circ Res; 2011 Oct; 109(9):1044-54. PubMed ID: 21885831
[TBL] [Abstract][Full Text] [Related]
11. Autologous transplantation of CD133+ BM-derived stem cells as a therapeutic option for dilatative cardiomyopathy.
Ghodsizad A; Ruhparwar A; Marktanner R; Borowski A; Mohammad Hasani MR; Poll L; Vshivkov I; Stoldt V; Voelkel T; Piechaczek C; Burchardt ER; Stockschlaeder M; Sucker C; Gams E; Klein HM
Cytotherapy; 2006; 8(3):308-10. PubMed ID: 16793739
[TBL] [Abstract][Full Text] [Related]
12. Stem cell therapy for the broken heart: mini-organ transplantation.
Mansour S; Roy DC; Lemieux B; Ouellet C; Stevens LM; Noiseux N
Transplant Proc; 2009 Oct; 41(8):3353-7. PubMed ID: 19857748
[TBL] [Abstract][Full Text] [Related]
13. Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients.
Feller N; van der Pol MA; Waaijman T; Weijers GW; Westra G; Ossenkoppele GJ; Schuurhuis GJ
Clin Cancer Res; 2005 Jul; 11(13):4793-801. PubMed ID: 16000576
[TBL] [Abstract][Full Text] [Related]
14. Impact of intracoronary injection of CD133+ bone marrow stem cells on coronary atherosclerotic progression in patients with STEMI: a COMPARE-AMI IVUS substudy.
Qiu F; Maehara A; El Khoury R; Généreux P; LaSalle L; Mintz GS; Noiseux N; Roy DC; Gobeil F; Stevens LM; Reeves F; Leclerc G; Rivard A; Mansour S
Coron Artery Dis; 2016 Jan; 27(1):5-12. PubMed ID: 26340545
[TBL] [Abstract][Full Text] [Related]
15. Intracoronary infusion of selected autologous bone marrow stem cells improves longitudinal myocardial strain and strain rate in patients with old anterior myocardial infarction without recent revascularization.
Karatasakis G; Leontiadis E; Peristeri I; Manginas A; Goussetis E; Graphakos S; Papadakis E; Cokkinos DV
Eur J Echocardiogr; 2010 Jun; 11(5):440-5. PubMed ID: 20308191
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of bone marrow cell homing into the infarcted human myocardium.
Hofmann M; Wollert KC; Meyer GP; Menke A; Arseniev L; Hertenstein B; Ganser A; Knapp WH; Drexler H
Circulation; 2005 May; 111(17):2198-202. PubMed ID: 15851598
[TBL] [Abstract][Full Text] [Related]
17. Impaired mobilization of CD133(+) bone marrow-derived circulating progenitor cells with an increased number of diseased coronary arteries in ischemic heart disease patients with diabetes.
Turan RG; Turan CH; Bozdag-Turan I; Ortak J; Akin I; Kische S; Schneider H; Kleinfeldt T; Rehders TC; Rauchhaus M; Adolph E; Amen S; Hermann T; Yokus S; Brehm M; Steiner S; Sahin K; Nienaber CA; Ince H
Circ J; 2011; 75(11):2635-41. PubMed ID: 21828932
[TBL] [Abstract][Full Text] [Related]
18. Safety analysis and improved cardiac function following local autologous transplantation of CD133(+) enriched bone marrow cells after myocardial infarction.
Ahmadi H; Baharvand H; Ashtiani SK; Soleimani M; Sadeghian H; Ardekani JM; Mehrjerdi NZ; Kouhkan A; Namiri M; Madani-Civi M; Fattahi F; Shahverdi A; Dizaji AV
Curr Neurovasc Res; 2007 Aug; 4(3):153-60. PubMed ID: 17691968
[TBL] [Abstract][Full Text] [Related]
19. Full GMP-compliant validation of bone marrow-derived human CD133(+) cells as advanced therapy medicinal product for refractory ischemic cardiomyopathy.
Belotti D; Gaipa G; Bassetti B; Cabiati B; Spaltro G; Biagi E; Parma M; Biondi A; Cavallotti L; Gambini E; Pompilio G
Biomed Res Int; 2015; 2015():473159. PubMed ID: 26495296
[TBL] [Abstract][Full Text] [Related]
20. [Detection and analysis of CD271, CD133 and CD34 expressions in bone marrow cells by flow cytometry with three color fluorescence labelling].
Zhou J; Zhu B; DU HY; Sun TS; Zhang CH; Yang LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):133-6. PubMed ID: 19236764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
